HDAC6 Deacetylase Activity Is Required for Hypoxia-Induced Invadopodia Formation and Cell Invasion

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Arsenault, Dominique ^a   Brochu Gaudreau, Karine ^a   Charbonneau, Martine ^a   Dubois, Claire M ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HISTONE DEACETYLASE 6; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME REGULATION; GENE SILENCING; GENE TRANSLOCATION; HUMAN; HUMAN CELL; HYPOXIA; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANOXIA; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL NUCLEUS; CELL PROLIFERATION; CELL SURFACE EXTENSIONS; EXTRACELLULAR MATRIX; FIBROSARCOMA; FLUORESCENT ANTIBODY TECHNIQUE; HISTONE DEACETYLASES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOPRECIPITATION; NEOPLASM INVASIVENESS; PROTEIN TRANSPORT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 84873556996     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055529     Document Type: Article

References (92)

1. Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, et al. (2003) Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 63: 1138-1143.
2. McMahon S, Grondin F, McDonald PP, Richard DE, Dubois CM, (2005) Hypoxia-enhanced expression of the proprotein convertase furin is mediated by hypoxia-inducible factor-1: impact on the bioactivation of proproteins. J Biol Chem 280: 6561-6569.
3. Zhang H, Akman HO, Smith EL, Zhao J, Murphy-Ullrich JE, et al. (2003) Cellular response to hypoxia involves signaling via Smad proteins. Blood 101: 2253-2260.
4. Akman HO, Zhang H, Siddiqui MA, Solomon W, Smith EL, et al. (2001) Response to hypoxia involves transforming growth factor-beta2 and Smad proteins in human endothelial cells. Blood 98: 3324-3331.
5. Shi YF, Fong CC, Zhang Q, Cheung PY, Tzang CH, et al. (2007) Hypoxia induces the activation of human hepatic stellate cells LX-2 through TGF-beta signaling pathway. FEBS Lett 581: 203-210.
6. Yoon SO, Shin S, Mercurio AM, (2005) Hypoxia stimulates carcinoma invasion by stabilizing microtubules and promoting the Rab11 trafficking of the alpha6beta4 integrin. Cancer Res 65: 2761-2769.
7. Arsenault D, Lucien F, Dubois CM (2011) Hypoxia enhances cancer cell invasion through relocalization of the proprotein convertase furin from the trans-Golgi network to the cell surface. J Cell Physiol.
8. Munoz-Najar UM, Neurath KM, Vumbaca F, Claffey KP, (2006) Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene 25: 2379-2392.
9. Lin HH, Li X, Chen JL, Sun X, Cooper FN, et al. (2012) Identification of an AAA ATPase VPS4B-dependent pathway that modulates epidermal growth factor receptor abundance and signaling during hypoxia. Mol Cell Biol 32: 1124-1138.
10. Lucien F, Brochu-Gaudreau K, Arsenault D, Harper K, Dubois CM, (2011) Hypoxia-induced invadopodia formation involves activation of NHE-1 by the p90 ribosomal S6 kinase (p90RSK). PLoS One 6: e28851.
11. Park SY, Jun JA, Jeong KJ, Heo HJ, Sohn JS, et al. (2011) Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. Oncol Rep 25: 1677-1681.
12. Ahmad M, Hamid A, Hussain A, Majeed R, Qurishi Y, et al. (2012) Understanding Histone Deacetylases in the Cancer Development and Treatment: An Epigenetic Perspective of Cancer Chemotherapy. DNA Cell Biol.
13. Grozinger CM, Hassig CA, Schreiber SL, (1999) Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc Natl Acad Sci U S A 96: 4868-4873.
14. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, et al. (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202.
15. Kim HJ, Bae SC, (2011) Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 3: 166-179.
16. Fukuda H, Sano N, Muto S, Horikoshi M, (2006) Simple histone acetylation plays a complex role in the regulation of gene expression. Brief Funct Genomic Proteomic 5: 190-208.
17. Lin HY, Chen CS, Lin SP, Weng JR, Chen CS, (2006) Targeting histone deacetylase in cancer therapy. Med Res Rev 26: 397-413.
18. Hess-Stumpp H, (2005) Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur J Cell Biol 84: 109-121.
19. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, et al. (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109: 31-39.
20. Modesitt SC, Sill M, Hoffman JS, Bender DP, (2008) A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 109: 182-186.
21. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, et al. (2008) A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 14: 7138-7142.
22. Bruserud O, Stapnes C, Ersvaer E, Gjertsen BT, Ryningen A, (2007) Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr Pharm Biotechnol 8: 388-400.
23. Bazzaro M, Lin Z, Santillan A, Lee MK, Wang MC, et al. (2008) Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res 14: 7340-7347.
24. Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y, et al. (2008) The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res 68: 7561-7569.
25. Sakuma T, Uzawa K, Onda T, Shiiba M, Yokoe H, et al. (2006) Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol 29: 117-124.
26. Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, et al. (2005) Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 19: 1751-1759.
27. Shan B, Yao TP, Nguyen HT, Zhuo Y, Levy DR, et al. (2008) Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition. J Biol Chem 283: 21065-21073.
28. Rey M, Irondelle M, Waharte F, Lizarraga F, Chavrier P, (2011) HDAC6 is required for invadopodia activity and invasion by breast tumor cells. Eur J Cell Biol 90: 128-135.
29. Tsunoda K, Oikawa H, Tada H, Tatemichi Y, Muraoka S, et al. (2011) Nucleus Accumbens-Associated 1 Contributes to Cortactin Deacetylation and Augments the Migration of Melanoma Cells. J Invest Dermatol.
30. Zhang X, Yuan Z, Zhang Y, Yong S, Salas-Burgos A, et al. (2007) HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell 27: 197-213.
31. Kaluza D, Kroll J, Gesierich S, Yao TP, Boon RA, et al. (2011) Class IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactin. EMBO J 30: 4142-4156.
32. Nogales E, (2000) Structural insights into microtubule function. Annu Rev Biochem 69: 277-302.
33. Dong C, Li Z, Alvarez R Jr, Feng XH, Goldschmidt-Clermont PJ, (2000) Microtubule binding to Smads may regulate TGF beta activity. Mol Cell 5: 27-34.
34. Inoue A, Yoshida N, Omoto Y, Oguchi S, Yamori T, et al. (2002) Development of cDNA microarray for expression profiling of estrogen-responsive genes. J Mol Endocrinol 29: 175-192.
35. Wang J, Lin A, Lu L, (2010) Effect of EGF-induced HDAC6 activation on corneal epithelial wound healing. Invest Ophthalmol Vis Sci 51: 2943-2948.
36. Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, Mueller SC, (2006) Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res 66: 3034-3043.
37. Baldassarre M, Pompeo A, Beznoussenko G, Castaldi C, Cortellino S, et al. (2003) Dynamin participates in focal extracellular matrix degradation by invasive cells. Mol Biol Cell 14: 1074-1084.
38. Lizarraga F, Poincloux R, Romao M, Montagnac G, Le Dez G, et al. (2009) Diaphanous-related formins are required for invadopodia formation and invasion of breast tumor cells. Cancer Res 69: 2792-2800.
39. Sakurai-Yageta M, Recchi C, Le Dez G, Sibarita JB, Daviet L, et al. (2008) The interaction of IQGAP1 with the exocyst complex is required for tumor cell invasion downstream of Cdc42 and RhoA. J Cell Biol 181: 985-998.
40. Wolf K, Wu YI, Liu Y, Geiger J, Tam E, et al. (2007) Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol 9: 893-904.
41. Yamaguchi H, Lorenz M, Kempiak S, Sarmiento C, Coniglio S, et al. (2005) Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin. J Cell Biol 168: 441-452.
42. Kimura F, Iwaya K, Kawaguchi T, Kaise H, Yamada K, et al. (2010) Epidermal growth factor-dependent enhancement of invasiveness of squamous cell carcinoma of the breast. Cancer Sci 101: 1133-1140.
43. Desmarais V, Yamaguchi H, Oser M, Soon L, Mouneimne G, et al. (2009) N-WASP and cortactin are involved in invadopodium-dependent chemotaxis to EGF in breast tumor cells. Cell Motil Cytoskeleton 66: 303-316.
44. Rottiers P, Saltel F, Daubon T, Chaigne-Delalande B, Tridon V, et al. (2009) TGFbeta-induced endothelial podosomes mediate basement membrane collagen degradation in arterial vessels. J Cell Sci 122: 4311-4318.
45. Mandal S, Johnson KR, Wheelock MJ, (2008) TGF-beta induces formation of F-actin cores and matrix degradation in human breast cancer cells via distinct signaling pathways. Exp Cell Res 314: 3478-3493.
46. Baldassarre M, Ayala I, Beznoussenko G, Giacchetti G, Machesky LM, et al. (2006) Actin dynamics at sites of extracellular matrix degradation. Eur J Cell Biol 85: 1217-1231.
47. Blanchette F, Rivard N, Rudd P, Grondin F, Attisano L, et al. (2001) Cross-talk between the p42/p44 MAP kinase and Smad pathways in transforming growth factor beta 1-induced furin gene transactivation. J Biol Chem 276: 33986-33994.
48. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR, (2008) Cadherin switching. J Cell Sci 121: 727-735.
49. Shintani Y, Wheelock MJ, Johnson KR, (2006) Phosphoinositide-3 kinase-Rac1-c-Jun NH2-terminal kinase signaling mediates collagen I-induced cell scattering and up-regulation of N-cadherin expression in mouse mammary epithelial cells. Mol Biol Cell 17: 2963-2975.
50. Maeda M, Johnson KR, Wheelock MJ, (2005) Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition. J Cell Sci 118: 873-887.
51. Dubois CM, Blanchette F, Laprise MH, Leduc R, Grondin F, et al. (2001) Evidence that furin is an authentic transforming growth factor-beta1-converting enzyme. Am J Pathol 158: 305-316.
52. Cui Y, Jean F, Thomas G, Christian JL, (1998) BMP-4 is proteolytically activated by furin and/or PC6 during vertebrate embryonic development. EMBO J 17: 4735-4743.
53. Jean F, Stella K, Thomas L, Liu G, Xiang Y, et al. (1998) alpha1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent. Proc Natl Acad Sci U S A 95: 7293-7298.
54. Feng XH, Derynck R, (2005) Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol 21: 659-693.
55. Basu RK, Hubchak S, Hayashida T, Runyan CE, Schumacker PT, et al. (2011) Interdependence of HIF-1alpha and TGF-beta/Smad3 signaling in normoxic and hypoxic renal epithelial cell collagen expression. Am J Physiol Renal Physiol 300: F898-905.
56. Chae KS, Kang MJ, Lee JH, Ryu BK, Lee MG, et al. (2011) Opposite functions of HIF-alpha isoforms in VEGF induction by TGF-beta1 under non-hypoxic conditions. Oncogene 30: 1213-1228.
57. Sawyer JS, Anderson BD, Beight DW, Campbell RM, Jones ML, et al. (2003) Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. J Med Chem 46: 3953-3956.
58. Jinnin M, Ihn H, Tamaki K, (2006) Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol 69: 597-607.
59. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, et al. (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417: 455-458.
60. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL, (2003) Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 100: 4389-4394.
61. Dubois CM, Laprise MH, Blanchette F, Gentry LE, Leduc R, (1995) Processing of transforming growth factor beta 1 precursor by human furin convertase. J Biol Chem 270: 10618-10624.
62. Scandura JM, Boccuni P, Massague J, Nimer SD, (2004) Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. Proc Natl Acad Sci U S A 101: 15231-15236.
63. Krasagakis K, Tholke D, Farthmann B, Eberle J, Mansmann U, et al. (1998) Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br J Cancer 77: 1492-1494.
64. Ito N, Kawata S, Tamura S, Takaishi K, Shirai Y, et al. (1991) Elevated levels of transforming growth factor beta messenger RNA and its polypeptide in human hepatocellular carcinoma. Cancer Res 51: 4080-4083.
65. Behzadian MA, Wang XL, Al-Shabrawey M, Caldwell RB, (1998) Effects of hypoxia on glial cell expression of angiogenesis-regulating factors VEGF and TGF-beta. Glia 24: 216-225.
66. Sato H, Kinoshita T, Takino T, Nakayama K, Seiki M, (1996) Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Lett 393: 101-104.
67. Yana I, Weiss SJ, (2000) Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol Biol Cell 11: 2387-2401.
68. Akhurst RJ, Derynck R, (2001) TGF-beta signaling in cancer-a double-edged sword. Trends Cell Biol 11: S44-51.
69. Massague J, (2008) TGFbeta in Cancer. Cell 134: 215-230.
70. Brown KA, Pietenpol JA, Moses HL, (2007) A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J Cell Biochem 101: 9-33.
71. Roberts AB, Tian F, Byfield SD, Stuelten C, Ooshima A, et al. (2006) Smad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev 17: 19-27.
72. Deckers M, van Dinther M, Buijs J, Que I, Lowik C, et al. (2006) The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 66: 2202-2209.
73. Valcourt U, Kowanetz M, Niimi H, Heldin CH, Moustakas A, (2005) TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Biol Cell 16: 1987-2002.
74. Piek E, Moustakas A, Kurisaki A, Heldin CH, ten Dijke P, (1999) TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J Cell Sci 112 (Pt 24): 4557-4568.
75. Wiercinska E, Naber HP, Pardali E, van der Pluijm G, van Dam H, et al. (2010) The TGF-beta/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Res Treat.
76. Nascimento CF, Gama-De-Souza LN, Freitas VM, Jaeger RG, (2010) Role of MMP9 on invadopodia formation in cells from adenoid cystic carcinoma. Study by laser scanning confocal microscopy. Microsc Res Tech 73: 99-108.
77. Chen WT, Wang JY, (1999) Specialized surface protrusions of invasive cells, invadopodia and lamellipodia, have differential MT1-MMP, MMP-2, and TIMP-2 localization. Ann N Y Acad Sci 878: 361-371.
78. Stegmuller J, Huynh MA, Yuan Z, Konishi Y, Bonni A, (2008) TGFbeta-Smad2 signaling regulates the Cdh1-APC/SnoN pathway of axonal morphogenesis. J Neurosci 28: 1961-1969.
79. Ju W, Ogawa A, Heyer J, Nierhof D, Yu L, et al. (2006) Deletion of Smad2 in mouse liver reveals novel functions in hepatocyte growth and differentiation. Mol Cell Biol 26: 654-667.
80. Gong K, Xing D, Li P, Hilgers RH, Hage FG, et al. (2011) cGMP inhibits TGF-beta signaling by sequestering Smad3 with cytosolic beta2-tubulin in pulmonary artery smooth muscle cells. Mol Endocrinol 25: 1794-1803.
81. Yang Y, Rao R, Shen J, Tang Y, Fiskus W, et al. (2008) Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Res 68: 4833-4842.
82. Mishra OP, Ashraf QM, Delivoria-Papadopoulos M, (2010) Hypoxia-induced activation of epidermal growth factor receptor (EGFR) kinase in the cerebral cortex of newborn piglets: the role of nitric oxide. Neurochem Res 35: 1471-1477.
83. Wang X, Schneider A, (2010) HIF-2alpha-mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia. Carcinogenesis 31: 1202-1210.
84. Kretzschmar M, Doody J, Massague J, (1997) Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature 389: 618-622.
85. Kretzschmar M, Doody J, Timokhina I, Massague J, (1999) A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. Genes Dev 13: 804-816.
86. Sasseville M, Ritter LJ, Nguyen TM, Liu F, Mottershead DG, et al. (2010) Growth differentiation factor 9 signaling requires ERK1/2 activity in mouse granulosa and cumulus cells. J Cell Sci 123: 3166-3176.
87. Deribe YL, Wild P, Chandrashaker A, Curak J, Schmidt MH, et al. (2009) Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6. Sci Signal 2: ra84.
88. Watabe M, Nakaki T, (2011) Protein kinase CK2 regulates the formation and clearance of aggresomes in response to stress. J Cell Sci 124: 1519-1532.
89. Mottet D, Ruys SP, Demazy C, Raes M, Michiels C, (2005) Role for casein kinase 2 in the regulation of HIF-1 activity. Int J Cancer 117: 764-774.
90. Wang S, Li X, Parra M, Verdin E, Bassel-Duby R, et al. (2008) Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7. Proc Natl Acad Sci U S A 105: 7738-7743.
91. Dallavalle S, Pisano C, Zunino F, (2012) Development and therapeutic impact of HDAC6-selective inhibitors. Biochem Pharmacol 84: 756-765.
92. Bennewith KL, Dedhar S, (2011) Targeting hypoxic tumour cells to overcome metastasis. BMC Cancer 11: 504.